Peak Bio Inc

Peak Bio Inc. is a clinical-stage biopharmaceutical company, which engages in the commercialization of therapeutics that aim to address the medical need of patients with inflammatory, rare and specialty diseases, and cancer. It focuses on the development of treatment of alpha-1 antitrypsin (AAT) deficiency (AATD), a genetic disorder that may result in lung disease or liver disease. The company is headquartered in Palo Alto, CA.

It has been a bumpy week and this Friday isn't any easier following the monthly jobs report. However, that doesn't seem to matter for Peak Bio (NASDAQ: PKBO ), which recently combined in a deal with Ignyte Acquisition.

What Is Going on With Peak Bio (PKBO) Stock Today?

Peak Bio, Inc. ("Peak Bio" or the "Company") (NASDAQ: PKBO), a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory diseases, today announced that it has entered into a Common Stock Purchase Agreement (the "Agreement") with White Lion Capital, LLC ("White Lion Capital"). The Agreement governs a committed equity facility that provides the Company with the right, without the obligation, to sell White Lion Capital up to $100 million of its common stock over a 36-month period, subject to certain limitations and conditions. The Company intends to use the net proceeds from the transaction for working capital to support its clinical and preclinical programs.

Peak Bio, Inc. Announces Closing of up to $100 Million Common Stock Purchase Transaction with White Lion Capital

Ignyte Acquisition Corp

NEW YORK--(BUSINESS WIRE)--Peak Bio Co., Ltd.

News for Peak Bio Inc Stock (PKBO)